Compare Stocks → Top Project Outperforms BTC in 2023… (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:BPTHNASDAQ:CNTXNASDAQ:NEXINASDAQ:PLXP Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBPTHBio-Path$4.03-0.2%$7.08$3.51▼$44.80$2.74M0.6622,634 shs32,291 shsCNTXContext Therapeutics$1.41+2.3%$1.10$0.47▼$1.69$20.28M2.1346,246 shs37,149 shsNEXINexImmune$5.61+1.8%$7.59$1.25▼$28.69$5.95M1.92.26 million shs7,203 shsPLXPPLx Pharma$0.00$0.02▼$0.04$603K3.7912.96 million shs3,000 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBPTHBio-Path+0.50%-9.42%-30.34%-58.69%-87.68%CNTXContext Therapeutics+11.29%+20.00%+22.11%+20.00%+135.86%NEXINexImmune-3.16%-3.67%-22.18%+159.91%-45.30%PLXPPLx Pharma0.00%0.00%0.00%0.00%-99.84%AI to Meet the Same Fate as EVs? (Ad)When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… Simply click here to read Porter’s warning on The Big AI Die-Up now.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBPTHBio-Path1.3642 of 5 stars3.52.00.00.02.30.00.6CNTXContext Therapeutics1.8416 of 5 stars3.53.00.00.02.80.00.6NEXINexImmuneN/AN/AN/AN/AN/AN/AN/AN/APLXPPLx PharmaN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBPTHBio-Path3.00Buy$40.00892.56% UpsideCNTXContext Therapeutics3.00Buy$4.00182.85% UpsideNEXINexImmuneN/AN/AN/AN/APLXPPLx PharmaN/AN/AN/AN/ACurrent Analyst RatingsLatest BPTH, PLXP, CNTX, and NEXI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/27/2024BPTHBio-PathRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $40.003/21/2024CNTXContext TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$5.00 ➝ $4.00(Data available from 3/28/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBPTHBio-PathN/AN/AN/AN/A$0.71 per shareN/ACNTXContext TherapeuticsN/AN/AN/AN/A$0.74 per shareN/ANEXINexImmuneN/AN/AN/AN/A$33.43 per shareN/APLXPPLx Pharma$4.54M0.00N/AN/A$1.30 per share0.00Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBPTHBio-Path-$16.08M-$40.80N/AN/AN/AN/A-375.74%-248.63%5/10/2024 (Estimated)CNTXContext Therapeutics-$23.96M-$1.50N/AN/AN/AN/A-115.50%-97.04%5/8/2024 (Estimated)NEXINexImmune-$62.51M-$42.15N/A∞N/AN/A-216.33%-157.05%N/APLXPPLx Pharma-$46.13M-$1.85N/AN/AN/A-606.91%-291.11%-119.43%N/ALatest BPTH, PLXP, CNTX, and NEXI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/8/202412/31/2023BPTHBio-Path-$5.40-$5.40N/AN/AN/AN/A DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBPTHBio-PathN/AN/AN/AN/AN/ACNTXContext TherapeuticsN/AN/AN/AN/AN/ANEXINexImmuneN/AN/AN/AN/AN/APLXPPLx PharmaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBPTHBio-PathN/A1.601.60CNTXContext TherapeuticsN/A3.833.83NEXINexImmuneN/A1.661.66PLXPPLx PharmaN/A4.794.28OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBPTHBio-Path5.74%CNTXContext Therapeutics14.03%NEXINexImmune9.85%PLXPPLx Pharma21.19%Insider OwnershipCompanyInsider OwnershipBPTHBio-Path3.05%CNTXContext Therapeutics6.66%NEXINexImmune19.40%PLXPPLx Pharma8.95%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBPTHBio-Path10680,000658,000OptionableCNTXContext Therapeutics5N/AN/ANot OptionableNEXINexImmune221.06 million853,000Not OptionablePLXPPLx Pharma1629.14 million26.53 millionNot OptionableBPTH, PLXP, CNTX, and NEXI HeadlinesSourceHeadlineProtalix Biotherapeutics Inc (PLX)investing.com - January 30 at 9:00 AMVertex Pharmaceuticals Inc VRTXmorningstar.com - January 22 at 7:59 PMVietnam National Petroleum Group (PLX)investing.com - October 23 at 10:13 AMPLx Pharma Inc (PLXPQ)uk.investing.com - August 21 at 4:54 AMPharmaceutical R&D: the road to positive returnsnature.com - July 16 at 9:22 AMPLXPQ PLx Pharma Inc.seekingalpha.com - April 21 at 11:49 PMPLx Pharma Inc. Enters into a Stalking Horse Asset Purchase Agreement to Sell VAZALORE(R) and Substantially All of its Assetsmarketwatch.com - April 13 at 10:45 PMWhy PLx Pharma Shares Are Nosediving Todaymsn.com - April 12 at 4:03 PMWhy iMedia Brands Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarketmsn.com - April 12 at 10:33 AMWhy PLx Pharma Shares Are Down Over 40% Tuesdaymsn.com - April 11 at 11:47 PMPLx Pharma Inc. Receives Nasdaq Delisting Noticefinance.yahoo.com - April 11 at 6:43 PMShort Volatility Alert: Plx Pharma Incmsn.com - April 11 at 1:42 PMPLx Pharma's Return On Capital Employed Insightsmsn.com - December 22 at 2:37 PMPLx Pharma (PLXP) Q3 2022 Earnings Call Transcriptseekingalpha.com - November 11 at 11:44 AMPLx Pharma down after Q3 revenue fell 94% Y/Yseekingalpha.com - November 11 at 11:44 AMPLx Pharma Inc. Reports Third Quarter 2022 Results and Provides Business Updatefinance.yahoo.com - November 10 at 8:33 PMPLx Pharma, Inc. (PLXP) Reports Q3 Loss, Misses Revenue Estimatesfinance.yahoo.com - November 10 at 8:33 PMEarnings Preview: PLx Pharmamsn.com - November 10 at 3:32 PMPLx Pharma Inc. to Report Third Quarter 2022 Financial Results on November 11, 2022, and Provide Business Updatefinance.yahoo.com - October 26 at 12:57 PMBaseball Legend John Smoltz Featured on PLx Pharma’s Social Channelsfinance.yahoo.com - September 12 at 9:15 PMPLx Pharma Inc. (NASDAQ:PLXP) drops to US$21m and insiders who purchased earlier this year lose another US$52kfinance.yahoo.com - September 5 at 11:30 AMPLXP Aug 2022 5.000 callfinance.yahoo.com - August 20 at 9:18 PMPLx Pharma downgraded at Oppenheimer after Q2 missseekingalpha.com - August 15 at 2:42 PMPLx Pharma to Explore Strategic Alternatives, Reduces Teammarketwatch.com - August 12 at 11:28 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsBio-PathNASDAQ:BPTHBio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 (BP1002) for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 (BP1003) for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and BP1001-A for the treatment of solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.Context TherapeuticsNASDAQ:CNTXContext Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors in the United States. It develops CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.NexImmuneNASDAQ:NEXINexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage. The company was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.PLx PharmaNASDAQ:PLXPPLx Pharma, Inc. is a late-stage specialty pharmaceutical company, which engages in the development and commercialization of technology platform for approved drugs. It offers PLxGuard delivery system, which uses surface acting lipids, such as phospholipids and free fatty acids, to modify the physiochemical properties of various drugs with a targeted release to select portions of the gastrointestinal (GI) tract. The company was founded by Ronald R. Zimmerman on November 12, 2002 and is headquartered in Sparta, NJ. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.